Paliperidone Teva (Paliperidone Palmitate)

Paliperidone palmitate is an atypical antipsychotic indicated for disorders that involve dopamine dysregulation:

• Schizophrenia: improves psychotic symptoms and reduces risk of relapse when administered as a monthly injection.
• Schizoaffective disorder: stabilises mood and psychotic features, supporting long‑term disease control.
• Maintenance therapy for schizophrenia: provides consistent plasma levels to minimise breakthrough episodes.
• Adjunctive treatment in bipolar‑type conditions when other therapies are insufficient, offering a long‑acting option.
• Preventive management in patients with a history of medication non‑adherence.

• Paliperidone palmitate is a pro‑drug that slowly releases paliperidone after intramuscular injection. The active moiety antagonises dopamine D2 and serotonin 5‑HT2A receptors, modulating neurotransmission in mesolimbic and mesocortical pathways. This receptor blockade reduces positive and negative psychotic symptoms while also influencing serotonergic activity that contributes to mood stabilization.

Paliperidone palmitate may cause a range of adverse reactions. Monitoring and patient education are essential to manage these effects.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the injection site.
• Headache: transient and often resolves without intervention.
• Weight gain: gradual increase in body mass index.
• Restlessness (akathisia): feeling of inner restlessness or inability to stay still.
• Drowsiness or somnolence: mild sedation, especially after the first few doses.
• Constipation: reduced bowel motility leading to infrequent stools.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever, rigidity, autonomic instability.
• Tardive dyskinesia: persistent involuntary movements, potentially irreversible.
• Hyperglycaemia or new‑onset diabetes: significant rise in blood glucose levels.
• Orthostatic hypotension: sudden drop in blood pressure upon standing, causing dizziness.
• Seizures: rare occurrence, particularly in patients with a seizure history.
• Elevated prolactin: galactorrhoea, menstrual disturbances, or sexual dysfunction.

Before initiating Paliperidone Teva, clinicians should assess individual risk factors and monitor patients regularly.

• Cardiovascular assessment: evaluate for history of arrhythmias or QT prolongation.
• Metabolic monitoring: check baseline glucose, lipid profile and weight.
• Psychiatric evaluation: ensure the patient is stable and understands the injection schedule.
• Pregnancy and lactation: weigh benefits against potential fetal or neonatal risks.
• Drug‑interaction review: verify concomitant medications do not increase cardiac or metabolic risk.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Paliperidone palmitate can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase paliperidone exposure.
• QT‑prolonging agents (e.g., quinidine, sotalol): additive risk of cardiac arrhythmia.
• CNS depressants (e.g., benzodiazepines, opioids): heightened sedation and respiratory depression.

Moderate Interactions (Monitor Closely)

• CYP2D6 substrates (e.g., metoprolol, atomoxetine): potential alteration in plasma levels.
• Antihypertensives: may enhance orthostatic hypotension.
• Antidiabetic drugs: monitor glucose as paliperidone can affect glycaemic control.